BioCardia has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s decision on May 13, 2024. On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated compliance with Listing Rule 5550(b)(1) of The Nasdaq Stock Market. Accordingly, the Panel has determined to continue the listing of the Company’s securities on the Nasdaq Stock Market and is closing this matter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
- Biotech Alert: Searches spiking for these stocks today
- BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
- BioCardia prices 2.4M shares at $3.00 in upsized public offering
- BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family